US Health Regulator Flags Concerns at Medtronic’s Diabetes Business

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Md., on Aug. 29, 2020. Andrew Kelly/Reuters

The U.S. health regulator has issued a warning letter to Medtronic Plc, highlighting certain concerns related to medical device quality management at its diabetes business, the company said on Wednesday.

Medtronic’s shares were down 6 percent at $104.95 in early trading, hitting their lowest in over a year.